Understand the source comparison
Survodutide vs Mazdutide vs Tirzepatide: Phase 3 Data Comparison
The clinical evidence separating these compounds became definitive in early 2026. The table below compares Phase 3 trial outcomes at 48 weeks. The standard endpoint for metabolic efficacy assessment. Survodutide GLP-1 / Glucagon 18.6% 11.4% 38% Strongest evide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The clinical evidence separating these compounds became definitive in early 2026. The table below compares Phase 3 trial outcomes at 48 weeks. The standard endpoint for metabolic efficacy assessment.
- Survodutide
- GLP-1 / Glucagon
- 18.6%
- 11.4%
- 38%
- Strongest evidence for metabolic rate elevation. Ideal for studies targeting energy expenditure pathways. Higher nausea rate limits tolerability in patient populations.
- Mazdutide
- GLP-1 / GIP / Glucagon
- 19.2%
- 9.8%
- 42%
- Best weight reduction outcome in any Phase 3 trial to date. Triple-receptor mechanism provides the broadest metabolic coverage but highest side effect burden. Research-grade supply remains limited as of Q1 2026.
- Tirzepatide (15mg)
- GLP-1 / GIP
- 15.7%
- 3.2%
- 34%
- Most established dual-agonist with FDA approval for obesity. Lower efficacy ceiling than glucagon-targeting compounds but better tolerability profile. Widely available in research-grade formulations.
- Semaglutide (2.4mg)
- GLP-1 only
- 14.9%
- 2.1%
- 30%
- Reference standard for GLP-1 monotherapy. Appetite suppression-driven mechanism. Minimal direct effect on energy expenditure. Extensive safety data from 72-week trials.
- Liraglutide (3.0mg)
- 8.4%
- 1.8%
- 28%
- First-generation GLP-1 agonist. Shortest half-life (13 hours) requires daily dosing. Lower efficacy than newer compounds but lowest cost for research procurement.
- The weight reduction data comes from intention-to-treat analysis in Phase 3 populations with BMI ≥30 or ≥27 with comorbidities. REE measurements are from metabolic chamber substudies published alongside primary trial results. Gastrointestinal adverse event rates include nausea, vomiting, and diarrhea during dose titration.
- What the data shows clearly: adding glucagon receptor activation to a GLP-1 backbone increases weight loss outcomes by 2–4 percentage points at 48 weeks. That difference compounds over longer treatment periods. A 72-week extension study of survodutide published in March 2026 found 22.1% mean reduction. No GLP-1 monotherapy has crossed the 20% threshold in any Phase 3 trial.